Effectiveness and safety of amantadine in parkinson disease-a meta-analysis

OBJECTIVE:

To evaluate the effectiveness and safety of amantadine in Parkinson’s disease.

METHODS:

Cochrane library, Pubmed database, Embase database, ISI database, CBM database, CNKI database, VIP database, Articles Database in computer were searched. Randomized controlled trials (RCT), systematic review (SR) or Meta analysis of amantadine vs placebo in Parkinson´s disease were selected, then quality evaluation and Meta-analysis were performed. The conclusions of the included SR and Metaanalysis
were taken into consideration.

RESULTS:

There were 9 RCTs of amantadine vs placebo in treating parkinson´s disease. The result showed that the efficacy of amantadine was better than placebo [RR 0. 14, 95% CI (0. 06, 0. 29), P ＜ 0. 000 01]. Amantadine was better than placebo to improve parkinson's symptoms [RR － 3. 21, 95% CI (－ 5. 88􀈤－ 0. 54), P = 0. 02]. When it comes to ADR, there was no significant difference between amantadine and placebo